These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31883646)

  • 1. Grey areas and open questions in neprilysin inhibition.
    Kodziszewska K; Sochanowicz B; Śmigielski W; Kruszewski M; Hryniewiecki T; Pączek L; Leszek P
    J Cardiol; 2020 Apr; 75(4):462-463. PubMed ID: 31883646
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
    Chang HY; Yin WH
    J Cardiol; 2020 Apr; 75(4):463-464. PubMed ID: 31882198
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan (Entresto) for Heart Failure.
    Cheng J
    Am Fam Physician; 2016 Oct; 94(8):611-612. PubMed ID: 27929235
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH
    J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chinese expert consensus on clinical application of angiotension-neprilysin inhibitor in patients with heart failure].
    ;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):662-670. PubMed ID: 35856222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
    Vergaro G; Passino C; Emdin M
    J Am Coll Cardiol; 2019 Jun; 73(23):3037-3038. PubMed ID: 31196468
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis.
    Okutucu S; Bursa N
    Int J Cardiol; 2019 Aug; 288():117. PubMed ID: 31101225
    [No Abstract]   [Full Text] [Related]  

  • 14. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
    Solomon SD; Claggett B; McMurray JJ; Hernandez AF; Fonarow GC
    Eur J Heart Fail; 2016 Oct; 18(10):1238-1243. PubMed ID: 27364182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
    James M; Manns B
    Circulation; 2018 Oct; 138(15):1515-1518. PubMed ID: 30354525
    [No Abstract]   [Full Text] [Related]  

  • 19. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.